secwatch / observer
8-K filed January 16, 2025, 6:59 PM ET ticker PTIX CIK 0001022899
regulatory confidence high sentiment neutral materiality 0.40

Protagenic Therapeutics gets Nasdaq notice for missing annual meeting; sets Feb 21, 2025 meeting

Protagenic Therapeutics, Inc.new

item 3.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001493152-25-002448
form_type
8-K
ticker
PTIX
cik
0001022899
company_name
Protagenic Therapeutics, Inc.new
filed_at
2025-01-16T23:59:59+00:00
discovered_at
2026-05-14T18:03:02.724396+00:00
generated_at
2026-05-27T23:42:24.101947+00:00
sec_items
["3.01"]
event_type
regulatory
sentiment
neutral
materiality_score
0.4
calibrated_materiality_score
0.4
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001493152-25-002448
json_url
https://secwatch.observer/filing/0001493152-25-002448.json
markdown_url
https://secwatch.observer/filing/0001493152-25-002448.md
text_url
https://secwatch.observer/filing/0001493152-25-002448.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1022899/000149315225002448/0001493152-25-002448-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1022899/000149315225002448/form8-k.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

fc67d2813ee1493d93d4b5c853e19dfd20d2504a

Protagenic Therapeutics, Inc.new received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

January 15, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications department (“Nasdaq”) regarding the timing of its annual meeting of shareholders. Nasd

SEC 8-K Item 3.01 confidence 0.9 SEC evidence

Comparable filings

LASE

Laser Photonics receives Nasdaq delisting notice for late Q1 2026 10-Q

Laser Photonics Corp May 22, 2026, 5:27 PM ET regulatory Items 3.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: regulatory similar materiality

This filing

January 15, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications department (“Nasdaq”) regarding the timing of its annual meeting of shareholders. Nasd

Comparable filing

received a notice from Nasdaq Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that since it had not received the Company’s Form 10-Q for the period ended March 31, 2026, the Company does not comply with Nasdaq’s Listing Rules for continued listing. Nasdaq stated that the Company has 60 days to submit a plan to regain compliance with respect to this delinquent report. Nasdaq can grant an exception to allow the Company to regain compliance up to a maximum of 180 calendar days from the due date of the Initial Delinquent Filing, or November 16, 2026. A copy of t

Filing page SEC filing

INV

Innventure regains Nasdaq compliance after appointing Bruce Brown to Audit Committee

Innventure, Inc. May 19, 2026, 5:45 PM ET regulatory Items 3.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: regulatory similar materiality

This filing

January 15, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications department (“Nasdaq”) regarding the timing of its annual meeting of shareholders. Nasd

Comparable filing

April 30, 2026, following the resignation of Daniel Hennessy from the Company’s Board of Directors (the “Board”) and Audit Committee effective April 29, 2026, the Company notified The Nasdaq Stock Market LLC (“Nasdaq”) t

Filing page SEC filing

MYPS

PLAYSTUDIOS receives Nasdaq Capital Market transfer; second compliance period to Nov 2, 2026

PLAYSTUDIOS, Inc. May 5, 2026, 7:59 PM ET regulatory Items 3.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: regulatory similar materiality

This filing

January 15, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications department (“Nasdaq”) regarding the timing of its annual meeting of shareholders. Nasd

Comparable filing

May 5, 2026, Nasdaq staff approved the Company’s application to transfer its listing to the Nasdaq Capital Market. The transfer will become effective at the opening of business on May 6, 2026 (the “Transfer Date”) and wi

Filing page SEC filing

GREE

Greenidge receives Nasdaq notice for audit committee non-compliance after director resignation

Greenidge Generation Holdings Inc. May 1, 2026, 7:59 PM ET regulatory Items 3.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: regulatory similar materiality

This filing

January 15, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications department (“Nasdaq”) regarding the timing of its annual meeting of shareholders. Nasd

Comparable filing

April 29, 2026, the Company received a notice from Nasdaq (the “Notice”) confirming the Company’s non-compliance with Nasdaq Listing Rule 5605(c)(2)(A) as a result of Mr. Fearn’s resignation from the Audit Committee. As

Filing page SEC filing

ARAI

Arrive AI regains compliance with Nasdaq MVPHS rule; delisting notice closed

Arrive AI Inc. April 28, 2026, 7:59 PM ET regulatory Items 3.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: regulatory similar materiality

This filing

January 15, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications department (“Nasdaq”) regarding the timing of its annual meeting of shareholders. Nasd

Comparable filing

March 31, 2026, Arrive AI Inc. (the “ Company ”) received a letter from The Nasdaq Listing Qualifications Department (the “ Staff ”) indicating that the Company’s common stock had failed to maintain a minimum market valu

Filing page SEC filing

ILLR

Triller gets Nasdaq bid-price exception until June 30, 2026

Triller Group Inc. June 2, 2026, 8:26 AM ET regulatory Items 3.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: regulatory

This filing

January 15, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications department (“Nasdaq”) regarding the timing of its annual meeting of shareholders. Nasd

Comparable filing

May 29, 2026, the Nasdaq Hearings Panel (the “Panel”) notified Triller Group Inc. (“Triller” or the “Company”) that the Panel determined to grant Triller an exception to the Listing Rules of The Nasdaq Stock Market (“Nasdaq” or the “Exchange”) until June 30, 2026 in order to regain compliance with Listing Rule 5550(a)(2) (the “Bid Price Rule”). As previously disclosed on April 24, 2026, following a successful appeal by the Company to the Nasdaq Stock Market Listing and Hearing Review Council (the “Listing Council”) which modified a previous December 26, 2025 decision by a Nasdaq Hearings Panel

Filing page SEC filing

ISPC

iSpecimen flagged for Nasdaq equity shortfall; equity $814K vs $2.5M minimum

iSpecimen Inc. June 1, 2026, 5:00 PM ET regulatory Items 3.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: regulatory

This filing

January 15, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications department (“Nasdaq”) regarding the timing of its annual meeting of shareholders. Nasd

Comparable filing

May 29, 2026, iSpecimen Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires a minimum of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Capital Market”). As reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026, the Company had stockholders’ equity of $814,038. Nasdaq noted that, as of May 29, 2026, the Company doe

Filing page SEC filing

GENC

Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing

GENCOR INDUSTRIES INC June 1, 2026, 4:09 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: regulatory

This filing

January 15, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications department (“Nasdaq”) regarding the timing of its annual meeting of shareholders. Nasd

Comparable filing

May 19, 2026, Gencor Industries, Inc. (the “Company”) received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company was not in compliance with the NYSE American LLC (“NYSE American”) continued listing standards as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) prior to May 18, 2026, the end of the extension period provided by Form 12b-25, and as a result was subject to the procedures set forth in Section 1007 of the NY

Filing page SEC filing

Source: SEC EDGAR
accession 0001493152-25-002448
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.